The Food and Drug Administration granted a priority review to Blincyto for the treatment of early-stage CD19-positive B-cell acute lymphoblastic leukemia. The Food and Drug Administration (FDA) ...
In the first clinical trial of dose-adjusted EPOCH along with inotuzumab ozogamicin (InO) in adults with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), Fred Hutch Cancer Center ...
Hosted on MSN
B-Cell Acute Lymphoblastic Leukemia for Adults: Causes, Symptoms, Diagnosis and Treatment
B-Cell Acute Lymphoblastic Leukemia for Adults: Causes, Symptoms, Diagnosis and Treatment: By Shreoshree Chakrabarty B-Cell Acute Lymphoblastic Leukemia (B-ALL) is a rare but aggressive form of ...
Among the efficacy evaluable patients, 42% achieved complete remission within 3 months. The Food and Drug Administration (FDA) has approved Aucatzyl ® (obecabtagene autoleucel; obe-cel) for the ...
Obe-cel is the first FDA-approved CAR T-cell therapy for B-ALL without a REMS requirement, based on the FELIX trial's positive outcomes. The FELIX trial reported a 63% complete remission rate, with 42 ...
Many older adults with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) have a relapse despite having a measurable residual disease (MRD)–negative complete remission with combination ...
SAN DIEGO -- Children with newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL) lived significantly longer without disease recurrence when they received the bispecific T-cell engager ...
This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Langston: We ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results